API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
The company has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC.
Lead Product(s): Mirtazapine
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dechra Pharmaceuticals Manufacturing
Deal Size: Undisclosed Upfront Cash: $43.0 million
Deal Type: Divestment March 16, 2020